Oncternal Therapeutics Inc (ONCT)

[hptaxis]

Link Update: SARM - ?AIH


http://www.pharmaceutical-technology.com/news/news41419.html

The chief executive officer of GTx Inc said his company's experimental Ostarine medicine to build muscle mass in cancer patients and in the elderly has enormous sales potential and is several years ahead of rival treatments in clinical trials.

Mitchell Steiner said Ostarine has greater sales potential than GTx' best-known experimental drug, called toremifene, which is now in late-stage studies to prevent prostate cancer and to prevent side effects caused by standard treatments for prostate cancer.

"I do believe the market ultimately is larger; it's a huge market," Steiner said, when asked if Ostarine – being developed in partnership with Merck & Co – had bigger sales potential than the company's flagship toremifene product.